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Background: Accumulation of amyloid beta (Aβ) may occur during healthy aging and
is a risk factor for Alzheimer Disease (AD). While individual Aβ-accumulation can be
measured non-invasively using Pittsburgh Compund-B positron emission tomography
(PiB-PET), Fluid-attenuated inversion recovery (FLAIR) is a Magnetic Resonance Imaging
(MRI) sequence, capable of indicating heterogeneous age-related brain pathologies
associated with tissue-edema. In the current study cognitively normal elderly subjects
were investigated for regional correlation of PiB- and FLAIR intensity.
Methods: Fourteen healthy elderly subjects without known history of cognitive
impairment received 11C-PiB-PET for estimation of regional Aβ-load. In addition, whole
brain T1-MPRAGE and FLAIR-MRI sequences were acquired at high field strength of 7
Tesla (7T). Volume-normalized intensities of brain regions were assessed by applying an
automated subcortical segmentation algorithm for spatial definition of brain structures.
Statistical dependence between FLAIR- and PiB-PET intensities was tested using
Spearman’s rank correlation coefficient (rho), followed by Holm–Bonferroni correction for
multiple testing.
Results: Neuropsychological testing revealed normal cognitive performance levels in all
participants. Mean regional PiB-PET and FLAIR intensities were normally distributed
and independent. Significant correlation between volume-normalized PiB-PET signals and
FLAIR intensities resulted for Hippocampus (right: rho = 0.86; left: rho = 0.84), Brainstem
(rho = 0.85) and left Basal Ganglia vessel region (rho = 0.82).
Conclusions: Our finding of a significant relationship between PiB- and FLAIR intensity
mainly observable in the Hippocampus and Brainstem, indicates regional Aβ associated
tissue-edema in cognitively normal elderly subjects. Further studies including clinical
populations are necessary to clarify the relevance of our findings for estimating individual
risk for age-related neurodegenerative processes such as AD.
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INTRODUCTION
Aging of the human brain is associated with increased accu-
mulation of extracellular Amyloid beta (Aβ) (Rodrigue et al.,
2012), which can be non-invasively measured by positron emis-
sion tomography using radioactively labeled stains such as
11-C Pittsburgh Compund-B (PiB-PET) (Klunk et al., 2004;
Vandenberghe et al., 2010). While spreading of Aβ-deposits is
a risk factor for age-related cognitive decline and a pathological
hallmark of Alzheimer Disease (AD) (Alzheimer, 1907; Hock and
Nitsch, 2000; Jack et al., 2009; Sperling et al., 2011), Aβ related
brain change may take place decades before manifestation of AD
as reflected by neuronal dysfunction, region-specific brain atro-
phy or subtle neuropsychological deficits (Mormino et al., 2009;
Sheline et al., 2010; Sperling et al., 2013; Steininger et al., 2014).
However, as data from postmortem neuropathological assess-
ment show that a considerable share of elderly individuals with
brain Aβ—deposition never experienced AD (Price and Morris,
1999; Knopman et al., 2003; Savva et al., 2009), investigation of
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Aβ-associated effects on brain tissue of non-demented individu-
als remains a research question of particular interest (Riudavets
et al., 2007; Iacono et al., 2008; Steffener and Stern, 2012).
Fluid-attenuated inversion recovery (FLAIR) is a magnetic res-
onance imaging (MRI) contrast based on tissue T2 prolongation
without cerebrospinal fluid (CSF) signal interference (De Coene
et al., 1992). While FLAIR-based contrasts are routinely used in
cerebral MRI for imaging of tissue-edema, regional FLAIR hyper-
intensities have been shown to relate to progression of many brain
diseases but also to reflect a wide variety of pathological con-
ditions associated with aging (Young et al., 2008; Neema et al.,
2009). FLAIR MRI significantly benefits from high magnetic field
strength, as shown by increased signal to noise ratio (SNR) when
performing FLAIR at 7 Tesla vs. 3 Tesla or 1.5 Tesla, respectively
(Visser et al., 2010; Zwanenburg et al., 2010).
Based on these earlier reports, we hypothesized that potential
Aβ—associated alterations in the aging brain may be indicated by
local tissue-edema as reflected by increased FLAIR signal before
manifestation of neurocognitive impairment and moreover take
place in brain regions with particular relevance for age-related
neurodegenerative pathology.
To answer this question, cognitively normal elderly subjects
were administered PiB-PET for measuring brain Aβ-load and
also MRI for quantitative assessment of regional FLAIR inten-
sities. FLAIR MRI was performed at 7 Tesla to achieve high
SNR and thus maximize sensitivity for detection of potential
Aβ related tissue change. An automated parcellation algorithm
was applied to PET- and MRI-volumes for topologic definition
of brain structures, making possible to investigate regional dis-
tribution of PiB and FLAIR signals as well as their potential
correlation.
METHODS
RECRUITMENT AND PHENOTYPING OF THE STUDY COHORT
Fourteen cognitively normal study participants aged between
60 and 79 years, without evidence for significant medical ill-
ness, were recruited as part of an ongoing study at our hospital
(Steininger et al., 2014). Study procedures are in concordance
with good clinical practice guidelines issued by the cantonal
ethics committee Zürich, Switzerland and Swiss Federal Institute
of Technology, respectively, (ETH Zürich), as well as with the
declaration of Helsinki (World_Medical_Association, 1991).
In brief, normal cognitive performance levels of all partic-
ipants was ascertained by psychiatric examination and neu-
ropsychological testing including an initial screen for cognitive
impairment [Mini Mental State Examination (MMSE); Folstein
et al., 1975], followed by specific assessment of cognitive sub-
domains: Language skills were tested by applying the short
version of the Boston Naming Test (BNT) from the CERAD-
Plus testbattery (Nicholas et al., 1988; Thalmann et al., 1997);
working memory performance was assessed by measuring mem-
ory span [digits forward and backward for short term mem-
ory assessment from the Wechsler Memory Scale—Revised
(WMS-R) (Howard, 1950; Härting et al., 2000)]; cognitive
flexibility was measured as an indicator of executive func-
tioning [ratio of Trail Making Test A and B (Reitan, 1958;
Tombaugh, 2004)]; memory performance was tested by applying
the Verbal Learning and Memory Test (VLMT, immediate,
delayed and supported recall) (Helmstaedter and Durwen, 1990;
Helmstaedter, 2001). The VLMT is a modified german ver-
sion of the auditory VLMT (Lezak, 1983; Müller et al., 1997).
Medical history was assessed to exclude presence of significant
medical illness in participants, complemented by Body mass
index (BMI) as a general indicator of health (Mackay, 2010)
(Table 1).
Exclusion criteria for the current study were: Cognitive
deficits indicative for mild cognitive impairment (MCI) or
dementia (Petersen et al., 1999; Winblad et al., 2004; Albert
et al., 2011), significant medication or drug abuse with possi-
ble effects on cognition, general MRI exclusion criteria, con-
traindications against vein puncture, clinically relevant changes
in red blood cell count, known allergy to the Carbon-11
based Pittsburgh Compund-B (PiB) positron emission tomog-
raphy (PET) tracer or any of its constituents, history of severe
allergic reactions to drugs or allergens, serious medical or
neuropsychiatric illness and significant exposure to radiation,
respectively.
CARBON-11 BASED PITTSBURGH COMPOUND-B POSITRON EMISSION
TOMOGRAPHY (PiB-PET) FOR ESTIMATION OF BRAIN Aβ
Carbon-11 based Pittsburgh Compound-B for positron emission
tomography (PiB-PET) based estimation of individual brain Aβ
load (Mathis et al., 2003; Klunk et al., 2004; Solbach et al., 2005)
was performed as reported earlier by our group at the PET Center
of the Division of Nuclear Medicine, Zürich University Hospital
utilizing a GE PET/CTDiscovery scanner (Steininger et al., 2014).
In brief, an individual dose of 350MBq of (11)carbon-labeled PiB
was injected into the cubital vein. Images were corrected for atten-
uation using a low-dose CT. Standard quantitative filtered back
projection algorithm including necessary corrections was applied.
Cerebral amyloid deposition values were extracted using
a standard routine as implemented in PMOD Brain Tool
software-package (PNEURO, Version 3.4, PMOD Technologies
Table 1 | Demographics of the studied sample including
neuropsychological test results.
Mean (SD)
N (Females/Males) 14 (6/8)
Age (years) 68.43 (5.3)
Education (years) 14.93 (2.13)
Body Mass Index (BMI) 25.83 (3.9)
Cortical PiB retention 1.23 (0.34)
Mini Mental State Examination (MMSE) 29.43 (0.94)
Boston Naming Test (BNT) 14.71 (0.61)
Memory span, digits forward 7.5 (1.09)
Memory span, digits backward 6.86 (1.66)
Trail Making Test (ratio TMT-A by TMT-B) 2.21 (0.66)
VLMT: immediate recall 11.43 (2.31)
VLMT: delayed recall 10.79 (2.55)
VLMT: supported recall 12 (1.96)
Indicated are mean values with standard deviations (SD).
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Ltd, Zürich, Switzerland). Late frame (minutes 50–70) values
were standardized by the cerebellar gray matter value, result-
ing in 3D-volumes of PiB-PET retention (matrix dimensions:
128× 128× 47, voxel size: 2.34× 2.34× 3.27mm).
MAGNETIC RESONANCE IMAGING (MRI) AT 7 TESLA
MRI images were obtained on a Philips 7 Tesla Achieva
whole-body scanner (Philips Healthcare, Best, The Netherlands)
equipped with a Nova Medical quadrature transmit head coil and
32-channel receive coil array. 14 healthy elderly controls were
scanned at the Institute for Biomedical Engineering (IBT) at the
Swiss Federal Institute of Technology at Zürich, Switzerland (ETH
Zürich). Acquired sequences included a high quality T1-weighted
3D MPRAGE sequence for structural brain image [TE/TR =
3.74ms/8.12ms; scan mode: 3D; total scan time: 654 s; FOV (ap,
fh, rl): 220× 157.50× 199.38mm; resolution (x, y, z): 256×
260× 175] for volumetric analysis of brain structures, and a
3D FLAIR sequence for assessment of regional tissue-edema
[TE/TR = 310.74/8000ms; scan mode: 3D; EPI = 1; total scan
time: 304 s; FOV (ap, fh, rl): 220× 120× 200.87mm; scan reso-
lution (x, y, z): 368× 366× 60].
STATISTICAL ANALYSIS OF MRI AND PiB-PET DATA
T1MPRAGE 3D volumes were postprocessed using an automated
subcortical parcellation algorithm (Freesurfer image analysis
suite; Fischl et al., 2004) for definition and volumetry of 29 cere-
bral anatomical structures included in the standard lookup table
(FreeSurferColorLUT), as performed in earlier projects of our
group (Unschuld et al., 2012a,b, 2013; Steininger et al., 2014). In
a second step, Freesurfer image analysis suite was used for coreg-
istration of FLAIR and PiB-PET volumes to the respective T1-
MPRAGE volume, allowing calculation of average intensity scores
for each of the 29 brain regions of interest (ROIs) in each of the
14 participants (individual regional PiB-PET- and FLAIR inten-
sity, respectively). All individual regional PiB-PET- and FLAIR
intensity scores were normalized to the respective ROI-volume
(PiB-PET/T1 and FLAIR/T1, respectively). Mean regional inten-
sity scores were calculated for each of the 29 ROIs based on the
respective 14 individual, volume normalized regional PiB-PET-
and FLAIR intensity scores, respectively. For subsequent statis-
tical analysis, z-standardized intensity scores (0 = mean) were
obtained as follows (zi = standardized intensity score; i = raw-
value PiB-PET- and FLAIR intensity, respectively; v = volume
of the respective brain region in voxels; μ = arithmetic mean; σ
= standard deviation): zi = [(i/v)–μ]/σ. For generation of stan-
dardized z-scores reflecting variance between subjects for each
region, μ and σ were calculated for 29 samples, representing the
assessed ROIs (individual regional PiB-PET- and FLAIR inten-
sity). To assess general variance of regional PiB-PET- and FLAIR
intensity, respectively, (mean regional PiB-PET- and FLAIR inten-
sity scores), μ and σ were calculated for 14 samples, representing
the included study participants. Normalicy of mean regional
intensities was tested by assuming a null hypothesis of normally
distributed mean PiB-PET- and FLAIR intensity values for each
region when applying Shapiro–Wilk test and Q-Q plots, as well as
Levene’s test for homogeneity of variances (IBM SPSS Statistics,
Armonk, NY, USA, Version 20.0). Statistical dependence was
tested, assuming a null hypothesis of independent regional PiB-
PET- and FLAIR intensity scores, using Pearson’s correlation
analysis (r). The MatLab software package [TheMathWorks, Inc.,
Natick, MA, USA, Version 8.3.0.532 (R2014a)] with Statistics
Toolbox (Version 9.0) and Symbolic Math Toolbox (Version 6.0)
were used to investigate each of the 29 ROIs for correlations
between regional PiB-PET- and FLAIR intensity of each partici-
pant (n = 14) using non-parametric Spearman’s rank correlation
(rho). To account for multiplicity bias, a correction for multiple
testing according to Holm–Bonferroni was applied to p-values
resulting from the 29 Spearman’s rank correlation tests (Holm,
1979).
RESULTS
NEUROPSYCHOLOGICAL ASSESSMENT INDICATES NORMAL TEST
PERFORMANCE OF STUDY POPULATION
MMSE did not reveal evidence for cognitive impairment in the
study population, as indicated by group-average [standard devia-
tion (SD)] test score of 29.43 (0.94). Consistently, neuropsycho-
logical assessment indicated individual test performances within
the normal range: Average performance in the BNT was 14.71
(0.61); Memory Span digits forward 7.5 (1.09), digits backward
6.86 (1.66); Trail Making Test ratio A by B: 2.24 (0.67) and results
of the VLMT (immediate, delayed, and supported recall, respec-
tively) were 11.43 (2.31), 10.79 (2.55), 12.0 (1.96). Mean age of
the studied population was 68 years [(SD) 5] years, mean time of
education was 14.93 years (SD 2.13). Mean BMI was 25.83 (SD
3.90) (Table 1).
MEAN REGIONAL PiB RETENTION SCORES AND FLAIR INTENSITIES
ARE NORMALLY DISTRIBUTED AND INDEPENDENT
Twenty-nine brain regions were defined by automated anatom-
ical labeling, making possible estimation of regional volumes
based on the T1-MR-data and respective average PiB reten-
tion scores and FLAIR intensities, respectively. All PiB-PET and
FLAIR intensities were normalized to the respective regional
volumes based on the T1-image (Table 2) and converted to
standardized z-scores. Tests of normality indicated normally dis-
tributed average regional PiB retention (df = 29, Shapiro–Wilk
= 0.95, p = 0.16) and FLAIR intensities (df = 29, Shapiro–
Wilk = 0.99, p = 0.95). Homogeneity of variances (σ2) of mean
regional FLAIR and PiB-PET intensities was indicated by non-
significant Levene’s Test [σ2 (FLAIR) = 0.57, σ2 (PiB-PET) =
0.55, p = 0.937] (Figure 1). No evidence of statistical dependence
between regional average PiB retention and FLAIR intensity could
be observed when Pearson’s correlation analysis was performed
(r = −0.18; p = 0.35). Ranking of average PiB-PET values by
size resulted in highest relative PiB retention for Pallidum [1.34
(0.08)], right ventral Diencephalon [1.17 (0.12)] and Brainstem
[1.12 (0.15)]. Lowest values resulted for Optic Chiasm [−1.99
(0.16)], left Accumbens Area [−0.79 (0.16)], and left Choroid
Plexus [−0.72 (0.17)] (Figure 2A). Highest mean regional FLAIR
intensities were observable for right Amygdala [1.52 (0.11)], left
Amygdala [1.36 (0.11)], and left Accumbens area [1.07 (0.11)].
Lowest values resulted for left Pallidum [−1.53 (0.13)], right
Pallidum [−1.36 (0.10)], and left Choroid Plexus [−1.15 (0.16)]
(Figure 2B).
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Table 2 | Volumes of brain structures as derived from the 7T T1 MPRAGE images as well as mean regional PiB-PET and FLAIR intensities,
normalized to volume.
ROI Volume T1 (ml) FLAIR/T1 PiB/T1 Spearman correlation FLAIR/T1 with PiB/T1
mean (s.e.m.)
rho −log(p) p (corrected)
Right-hippocampus 2.31 (0.28) 71.56 (11.33) 7.41 (0.92) 0.86 3.84 *0.0042
Brain-stem 19.8 (0.6) 6.58 (0.53) 0.83 (0.03) 0.85 3.56 *0.0076
Left-hippocampus 2.84 (0.48) 62.57 (13.5) 7.14 (1.18) 0.84 3.41 *0.0105
Left-vessel (basal ganglia) 0.11 (0.02) 1539.76 (280.43) 203.79 (53.32) 0.82 2.90 *0.0324
Left-choroid-plexus 0.66 (0.11) 163.48 (19.74) 23.58 (3.14) 0.73 2.05 0.22
Right-vessel (basal ganglia) 0.16 (0.02) 1211.58 (268.79) 120.21 (21.94) 0.69 1.86 0.33
Right-ventral DC 2.95 (0.12) 37.17 (3.6) 5.69 (0.27) 0.65 1.56 0.63
Right-caudate 3.31 (0.48) 40.22 (6.1) 4.77 (0.57) 0.64 1.56 0.6
Right-accumbens-area 0.45 (0.07) 364.38 (64.34) 38.44 (8.25) 0.61 1.41 0.82
Right-amygdala 1.29 (0.12) 126.13 (14.14) 11.12 (0.95) 0.60 1.32 0.95
Left-accumbens-area 0.52 (0.05) 296.24 (33.2) 30.17 (8.95) 0.57 1.16 0.99
Right-choroid-plexus 0.54 (0.06) 207.8 (27.3) 26.53 (3.19) 0.53 0.98 0.99
Optic-chiasm 0.15 (0.02) 918.46 (191.02) 71.34 (11.48) 0.50 0.84 0.99
Left-amygdala 1.06 (0.06) 143.13 (16.75) 12.63 (0.75) 0.49 0.79 0.99
Right-pallidum 1.29 (0.07) 68.34 (8.53) 13.84 (0.82) 0.49 0.83 0.99
CC_Posterior 0.94 (0.03) 105 (10.23) 16.6 (0.73) 0.43 0.59 0.99
CC_Central 0.36 (0.02) 335.93 (34.28) 35.2 (1.58) 0.39 0.47 0.99
Left-ventral DC 3.09 (0.15) 33.79 (3.31) 5.39 (0.29) 0.36 0.39 0.99
Left-thalamus-proper 6.29 (1.04) 18.29 (2.12) 2.63 (0.2) 0.35 0.36 0.99
Right-putamen 4.62 (0.38) 27.35 (3.27) 3.52 (0.29) 0.34 0.32 0.99
Left-caudate 2.48 (0.14) 48.99 (6.66) 5.25 (0.5) 0.29 0.20 0.99
Right-thalamus-proper 6.1 (0.58) 19.59 (1.92) 2.51 (0.2) 0.26 0.14 0.99
CC_Mid_Posterior 0.33 (0.02) 348.89 (35.27) 37.26 (1.76) 0.25 0.11 0.99
Right-cerebral-cortex 152.89 (4.28) 0.78 (0.05) 0.09 (0.01) 0.12 0.00 0.99
Left-cerebral-cortex 176.77 (9.06) 0.69 (0.06) 0.08 (0.01) 0.10 0.00 0.99
Left-putamen 4.91 (0.15) 22.88 (2.23) 3.04 (0.17) 0.03 0.00 0.99
CC_Anterior 0.83 (0.04) 143.91 (14.44) 17.86 (0.99) 0.01 0.00 0.99
CC_Mid_Anterior 0.41 (0.02) 268.19 (27.38) 32.29 (2.17) −0.05 0.00 0.99
Left-pallidum 1.51 (0.06) 55.95 (7.34) 11.07 (0.5) −0.20 0.00 0.97
Labels refer to anatomical ROIs defined by the FreeSurfer whole brain segmentation algorithm; DC, diencephalon; CC, corpus callosum. Indicated are mean values
with standard errors of the mean (SEM), as well as statistical dependence between regional PiB-PET and FLAIR intensities [Spearman rank correlation coefficients
(rho), significant relationships at p < 0.05 after correction for multiple testing are indicated by “*”].
INDIVIDUAL PiB RETENTION SCORES AND FLAIR INTENSITY
SIGNIFICANTLY CORRELATE FOR BRAIN REGIONS INCLUDING
HIPPOCAMPUS, BRAINSTEM, AND BASAL GANGLIA VESSELS
To identify region-specific relationships between Aβ—deposition
and FLAIR intensity, for each of the 29 investigated brain
regions a Spearman’s correlation coefficients were calcu-
lated based on individual regional PiB-PET- and FLAIR
intensity, as measured in each of the 14 participants. For
10 out of 29 brain regions a nominally significant rela-
tionship could be observed: Right Hippocampus (rho =
0.86, −log(p) = 3.84), Brainstem (rho = 0.85, −log(p)=
3.56), left Hippocampus (rho= 0.84, −log(p)= 3.41), left
Basal Ganglia vessels (rho = 0.82, −log(p)= 2.90), left
Choroid Plexus (rho = 0.73, −log(p)= 2.05), right Basal
Ganglia vessels (rho = 0.69, −log(p) = 1.86), right ven-
tral Diencephalon (rho = 0.65, −log(p) = 1.56), right
Caudate (rho = 0.64, −log(p) = 1.56), right Accumbens area
(rho = 0.61, −log(p) = 1.41), and right Amygdala (rho =
0.60, −log(p) = 1.32) (Table 2 and Figure 3A). When apply-
ing correction for multiple testing using the Holm–Bonferroni
method (Holm, 1979), four regions remained significant:
Right Hippocampus (p = 0.0042), Brainstem (p = 0.0076), left
Hippocampus (p = 0.011), left Basal Ganglia vessels (p = 0.32)
(Table 2 and Figure 3B).
DISCUSSION
Our data indicate a significant relationship between regional
Aβ—accumulation, as measured by PiB-PET, and tissue-edema,
as indicated by FLAIR intensity, in the hippocampus, brain-
stem and basal ganglia vessel region of cognitively normal
elderly adults. While, to our knowledge, this is the first study
to apply FLAIR MRI at high magnetic field strength of 7 Tesla
for investigation of Aβ associated brain change, our findings
are consistent with earlier reports on subcortical and limbic
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FIGURE 1 | Q-Q Plots of mean regional intensities (standardized
z-scores; 0 =mean, values indicate standard deviations from mean).
(A) Pittsburgh Compund-B positron emission tomography; (B)
Fluid-attenuated inversion recovery (FLAIR) 7 Tesla MRI (7T-FLAIR).
nuclei being particularly sensitive to age-related neurodegenera-
tive pathology.
PiB-PET is a well established neuroimaging method for
measuring brain Aβ deposition in elderly subjects with increased
risk for AD and to investigate brain change associated with Aβ—
accumulation (Klunk et al., 2004; Jack et al., 2009;Mormino et al.,
2009; Steininger et al., 2014). PiB-PET studies on populations
with sporadic AD are consistent with neuropathological data, as
they indicate Aβ—accumulation spreading from the neocortex to
the entire brain (Braak and Braak, 1991; Serrano-Pozo et al., 2011;
Jack and Holtzman, 2013). Preclinical stages in individuals with
genetic predisposition for familial AD however, appear to rather
be characterized by PiB retention in striatal regions (Klunk et al.,
2004; Bateman et al., 2012). A recent study investigating a large
sample of cognitively normal elderly subjects showed that subtle
increases of local Aβ indicate significant hypometabolism in AD-
signature regions including angular gyrus, posterior cingulate
and temporal lobe (Lowe et al., 2014). Moreover, an earlier study
reports correlations between increased Aβ-levels in temporal neo-
cortex and posterior cingulate cortex of cognitively normal elderly
with accelerated cortical atrophy (Chetelat et al., 2012). These
reports are consistent with the observation of significant spatial
variation of Aβ-deposition between brain regions (Price et al.,
2005; Mintun et al., 2006; Su et al., 2013) and highlight signifi-
cance of effects associated with Aβ-load in distinct brain regions
for progression of age-related neurodegeneration. In the current
study, region-specific investigation of Aβ-associated brain-change
was performed using whole brain segmentation tools provided
by the FreeSurfer software package, as demonstrated earlier to
provide high reliability for analysis of quantitative PiB-PET data
(Fischl et al., 2004; Su et al., 2013): By defining brain ROIs,
volumes were determined based on structural T1-MRI data
as well as respective intensities for PiB retention and FLAIR
contrast. The resulting regional average PiB-PET and FLAIR
intensities were normally distributed and independent, thus
minimizing probability of bias by brain region-specific variations
of sensitivity of either of the two contrasts applied. Each brain
region was tested for correlations between individual PiB-PET
and FLAIR intensities using Spearman’s correlation coefficient as
a non-parametric test allowing for the relatively small sample size
(Bonett and Wright, 2000), followed by correction for multiple
testing (Holm, 1979). In doing so, significant relationships
between PiB-PET and FLAIR intensities could be observed for
right and left Hippocampus, Brainstem and also a small region
including left Basal Ganglia vessels. As the FLAIR contrast reflects
a wide spectrum of pathological brain-tissue alterations associ-
ated with regional edema (Young et al., 2008; Neema et al., 2009;
Carlson et al., 2011), our finding is consistent with earlier reports
on signature-regions of AD primarily affected by age-related neu-
rodegeneration: The Hippocampus has been shown by numerous
studies to be particularly sensitive to aging related brain change
and AD in particular (de Leon et al., 1989; Frisoni et al., 2011;
Serrano-Pozo et al., 2011) and neurodegenerative processes can
be observed in gray matter nuclei located in Brainstem and Basal
Ganglia (Iseki et al., 1989; Parvizi et al., 2001; Simic et al., 2009;
Braak and Del Tredici, 2012; Brothers et al., 2013). Notably, sig-
nificant relationships with FLAIR intensity were not determined
by brain regions with highest PiB retention, which may support
considerations on pathological relevance of subtle increases of
Aβ in vulnerable brain regions (Mormino et al., 2012; Lowe
et al., 2014), potentially mediated by additional factors that may
determine resilience of distinct neuronal populations (Steffener
and Stern, 2012). Our data appear consistent with earlier reports
on a relationship between FLAIR hyperintensity and cerebral
Aβ-burden, as FLAIR intensity of white matter regions has
been shown to predict progression of Aβ-accumulation, thus
potentially representing a risk factor for neurodegeneration
and AD (Grimmer et al., 2012). However, focal tissue-edema
in the brain, as indicated by FLAIR hyperintensity, may also
be observed during treatment with antibodies targeted against
Aβ, thus potentially reflecting tissue processes associated with
clearance of Aβ (Frisoni, 2012; Sperling et al., 2012).
Limitations of the current study include the fact that while
SNR of the FLAIR sequence significantly benefit from high field
strengths (Visser et al., 2010; Zwanenburg et al., 2010) and
sensitivity for detection of subtle changes thus may have been
increased by using FLAIR MRI at 7 Tesla, findings nevertheless
need to be treated with caution, as clinical relevance of the
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FIGURE 2 | Standardized z-scores of regional average intensities, normalized by T1-volume, sorted in descending order. (A) Pittsburgh Compund-B
positron emission tomography; (B) Fluid-attenuated inversion recovery (FLAIR) 7 Tesla MRI (7T-FLAIR).
increased sensitivity has not been tested. While FLAIR MRI so
far has been used mainly for qualitative visual assessment of brain
tissue abnormalities (De Coene et al., 1992; Adams and Melhem,
1999), ROI-based quantification of FLAIR signal intensity has
been performed recently for investigation of brain pathology in
a context of acute stroke (Cheng et al., 2013). Nevertheless, as
FLAIR has limited capacities for quantification of single voxel-
intensities andMR-sequences implementing T2-relaxometry may
provide a better quantitative measure, this also needs to be con-
sidered as a potential limitation of the here performed approach
of correlating FLAIR intensities with PiB retention (Pell et al.,
2004; Deoni, 2010; Cheng et al., 2012). Another limitation is
the fact that as for the current study a cross-sectional design
was applied, no prospective inferences can be made regarding
effects of our findings on participant’s risk for AD. Moreover,
as high brainstem PiB uptake has been shown to indicate Aβ in
Parkinson’s disease with dementia (Maetzler et al., 2008), our
findings might also reflect brain change in a context of other
neurodegenerative pathologies than AD.
Taken together, our finding of a region specific correlation
between PiB retention, indicating Aβ-accumulation, and FLAIR
hyperintensities in cognitively normal elderly subjects is consis-
tent with earlier reports on Aβ-associated brain change taking
place decades before manifestation of AD as well as signature-
regions for neurodegenerative dementia in general. Additional
longitudinal studies are needed to clarify whether our find-
ings reflect changes associated with increased risk for age-related
brain disease or rather may indicate compensatory brain change,
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FIGURE 3 | (A) Relationship between individual regional PiB-PET and 7T
FLAIR intensities as indicated by spearman correlation analysis. Displayed are
regions with −log(p) > 1.3. Alpha = 0.05 after correction for multiple testing
for ROIs with −log(p) > 2.7, as indicated by red marker. Y-positions refer to
MNI space. (B) Brain regions with strongest relationship between individual
regional PiB-PET and 7T FLAIR, as indicated by significant spearman
correlation after correction of p-values for multiple testing
(Bonferroni–Holms). Each study-participant is represented by one dot.
resulting in normal cognitive performance despite prevalent Aβ-
burden.
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